Randomised non‐inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild‐to‐moderate ulcerative colitis
暂无分享,去创建一个
P. Rutgeerts | L. Stitt | M. Vandervoort | G. D'Haens | P. Rutgeerts | W. Sandborn | B. Feagan | V. Jairath | C. Parker | P. Hindryckx | L. Shackelton | G. Zou | Y. Marakhouski | R. Pai | D. Gilgen | S. Pimanov | E. Mikhailova | O. Levchenko | M. Horynski | C. Muller | N. Kharchenko | Pieter Hindryckx | W. Sandborn | Larry Stitt | M. Horyński
[1] Xuehua Piao,et al. A New Chinese Medicine Intestine Formula Greatly Improves the Effect of Aminosalicylate on Ulcerative Colitis , 2017, Evidence-based complementary and alternative medicine : eCAM.
[2] B. Feagan,et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. , 2016, The Cochrane database of systematic reviews.
[3] S. Travis,et al. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. , 2016, Journal of Crohn's & colitis.
[4] L. Stitt,et al. Development of interim patient‐reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials , 2015, Alimentary pharmacology & therapeutics.
[5] L. Stitt,et al. Development and validation of a histological index for UC , 2015, Gut.
[6] G. Sjøgaard,et al. Does training frequency and supervision affect compliance, performance and muscular health? A cluster randomized controlled trial. , 2015, Manual therapy.
[7] A. Bitton,et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. , 2015, Gastroenterology.
[8] M. Vandervoort,et al. Histologic Evaluation of Ulcerative Colitis: A Systematic Review of Disease Activity Indices , 2014, Inflammatory bowel diseases.
[9] Mamoru Watanabe,et al. Comparison of QD and TID Oral Mesalazine for Maintenance of Remission in Quiescent Ulcerative Colitis: A Double-blind, Double-dummy, Randomized Multicenter Study , 2013, Inflammatory bowel diseases.
[10] P. Rutgeerts,et al. The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis. , 2013, Gastroenterology.
[11] O. Dewit,et al. Randomised clinical trial: once‐ vs. twice‐daily prolonged‐release mesalazine for active ulcerative colitis , 2013, Alimentary pharmacology & therapeutics.
[12] C. Beauchemin,et al. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database , 2013, BMC Gastroenterology.
[13] S. Vermeire,et al. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Current management , 2012 .
[14] Andre Charlett,et al. The Feedback Intervention Trial (FIT) — Improving Hand-Hygiene Compliance in UK Healthcare Workers: A Stepped Wedge Cluster Randomised Controlled Trial , 2012, PloS one.
[15] L. Bazzano,et al. Long‐term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10‐year retrospective cohort from the veterans affairs healthcare system , 2012, Alimentary pharmacology & therapeutics.
[16] N. Ntoumanis,et al. Communication style and exercise compliance in physiotherapy (CONNECT). A cluster randomized controlled trial to test a theory-based intervention to increase chronic low back pain patients’ adherence to physiotherapists’ recommendations: study rationale, design, and methods , 2012, BMC Musculoskeletal Disorders.
[17] D. Gillespie,et al. One-year Investigator-blind Randomized Multicenter Trial Comparing Asacol 2.4 g Once Daily with 800 mg Three Times Daily for Maintenance of Remission in Ulcerative Colitis , 2011, Inflammatory bowel diseases.
[18] M. Sumner,et al. Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database , 2011, Digestive Diseases and Sciences.
[19] A. Vcev,et al. Randomised clinical trial: a comparative dose‐finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis , 2011, Alimentary pharmacology & therapeutics.
[20] A. Kornbluth,et al. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee , 2010, The American Journal of Gastroenterology.
[21] M. Campieri,et al. Clinical trial: ulcerative colitis maintenance treatment with 5‐ASA: a 1‐year, randomized multicentre study comparing MMX® with Asacol® , 2009, Alimentary pharmacology & therapeutics.
[22] T. Stijnen,et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[23] S. Schreiber,et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis , 2008, Gut.
[24] S. Kane,et al. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: Preliminary results from a randomized trial , 2008, Patient preference and adherence.
[25] Martin L. Brown,et al. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. , 2008, Clinical therapeutics.
[26] Xun Chen,et al. Choosing the analysis population in non‐inferiority studies: per protocol or intent‐to‐treat , 2006, Statistics in medicine.
[27] M. J. Shale,et al. Studies of compliance with delayed‐release mesalazine therapy in patients with inflammatory bowel disease , 2003, Alimentary pharmacology & therapeutics.
[28] D. Huo,et al. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[29] A. Öst,et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.
[30] R. Levy,et al. Increasing patient adherence to gastroenterology treatment and prevention regimens , 1999, American Journal of Gastroenterology.
[31] R. Newcombe,et al. Interval estimation for the difference between independent proportions: comparison of eleven methods. , 1998, Statistics in medicine.
[32] C. Sherbourne,et al. The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .
[33] W. Tremaine,et al. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. , 1987, The New England journal of medicine.
[34] E. Gracely,et al. Impact of multiple comparisons in randomized clinical trials. , 1987, The American journal of medicine.
[35] B. Feagan,et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. , 2012, The Cochrane database of systematic reviews.
[36] M. Kamm,et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[37] M. Kamm,et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. , 2007, Gastroenterology.
[38] S. Hanauer,et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. , 2003, The American journal of medicine.
[39] Ware J.E.Jr.,et al. THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .
[40] A. Williams. EuroQol : a new facility for the measurement of health-related quality of life , 1990 .
[41] A. Kasuya. EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.
[42] D. Hosmer,et al. Goodness of fit tests for the multiple logistic regression model , 1980 .